Piergiorgio Donati, Head of Technical
Operations and Program Management: Mr. Donati joined AC Immune in June 2018 as Director, Global Program Management, having
previously worked for AC Immune from 2011-2015 as Head of Manufacturing and Project Management. Between 2015 and 2018, Mr. Donati
was Head of CMC program development at Glenmark Pharmaceuticals and Biotech CMC Lead at Merck KGaA. Prior to 2011, he held R&D
positions at Abiogen, Merck Group and Serono. Mr. Donati holds a degree in Chemistry from the Technical Institute G.L. Bernini.
Sonia Poli, Ph.D., Head of Translational
Science: Dr. Poli joined AC Immune from Addex Therapeutics, where she worked for 13 years, and was promoted to Chief Scientific
Officer. Prior to Addex she spent seven years at Roche, most recently as Scientific Specialist in the CNS discovery Drug Metabolism
and Pharmacokinetics group. Dr. Poli holds a Ph.D. in Industrial Chemistry from Università degli Studi di Milano. Dr. Poli
is also a member of the Board of Directors of Dimerix Ltd.
Other Key Employees
Oliver Sol, M.D., Head of Clinical Team:
Prior to joining AC Immune, Dr. Olivier Sol was Clinical Director of Exonhit (Paris) and thereafter Medical & Regulatory Affairs
Director for Diaxonhit, where he was responsible for the development and medical validation of in-vitro diagnostic products in
cancer, infectious diseases and Alzheimer's disease. Dr. Sol spent his over 20-year career as a Medical Expert in several therapeutic
areas with a strong focus on central nervous system diseases, within pharmaceutical companies as Janssen, UCB-Pharma, GlaxoSmithKline
and Sanofi. He contributed to the clinical development of currently marketed drugs in epilepsy (topiramate and levetiracetam) and
galantamine in Alzheimer’s. He has also gained significant experience in the field of biological biomarkers. Dr. Sol holds
an M.D. from the Paris-Sud University (Paris-Saclay) with a specialization in Medical Biology.
Julian Gray, M.D., Ph.D., Clinical Advisor:
Dr. Gray has served as Clinical Advisor to our programs in neurodegenerative diseases since January 2007 and works in this function
exclusively for AC Immune. He has previously held the position of Head of CNS Therapeutics at Eisai Ltd in London leading the global
development of early and late-stage CNS projects in Alzheimer’s disease, Parkinson’s disease and other CNS areas. Prior
to this he served as Head of Alzheimer Clinical Research at Hoffmann-La Roche in Basel where he conducted large scale clinical
trials in the US and Europe. After his studies he was Medical Expert at Sandoz Pharmaceuticals in Basel undertaking clinical studies
of different compounds in dementia and Parkinson’s disease. Dr. Gray holds the title of a Specialist in Pharmaceutical Medicine
(Switzerland). He received his medical degree (MBBS) from the University of London, a BA and Ph.D. from the University of Oxford
and an MBA from the Oxford Brookes University.
Martin Velasco, Chairman and Director:
Mr. Velasco has served on our board of directors since December 2003. Martin Velasco is an entrepreneur and Business
Angel with extensive experience in the IT, medical and biotech areas. He serves on the board of directors or advisory board
of several other high-tech companies including: as Founder, Chairman and Chief Executive Officer of Anecova, an assisted reproductive
technology (ART) company and World Economic Forum Technology Pioneer 2008 as Chairman of the Supervisory Board of Cocomore, a digital
communications agency and IT services firm and as a Board Member of Aridhia, a Health Informatics company. Martin is also
the Founder of Infantia Foundation, a philanthropic organization aiding children in the developing world. He is an Ambassador of
BlueOrchard, the leading private microfinance investment advisory company and a member of the Strategic Advisory Board of the EPFL.
Detlev H. Riesner, Ph.D., Director:
Prof. Riesner has served on our board since 2004. He held the Chair of Biophysics at the Heinrich-Heine-University in Düsseldorf,
Germany from 1980 to 2007. He has also held the positions of Dean of the Science Faculty and Vice-President of Research. From 2007
through 2017, he was a member of the university’s Board of Trustees. He worked as a research fellow at Princeton University
and held a guest professorship at the department of Neurology at the University of California, San Francisco. Prof. Riesner is
a co-founder of Qiagen N.V., Netherlands, was a member and from 1999 to 2014 chairman of the Supervisory Board. He was also a member
of the supervisory boards of NewLab Bioquality AG, Erkrath, Direvo AG, Köln, and Alantos AG, Heidelberg. Currently, he is
the chairman of the Advisory Board of Evoxx Technologies GmbH, Monheim am Rhein. Prof. Riesner was a member of the scientific advisory
boards of the Friedrich-Löffler-Institut, Isle of Riems, and PrioNet and APRI, both Canada. He received the Max-Planck Forschungspreis
for International Co-operation and the Bundesverdienstkreuz 1. Klasse from the Bundespresident of Germany.